MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hancock, A. A.
Right arrow Articles by Marsh, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hancock, A. A.
Right arrow Articles by Marsh, C. L.

Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol

AA Hancock and CL Marsh

The binding of [3H]Hspiroperidol to D2 dopaminergic receptors in rat striatum was compared to the binding of [3H]dopamine to its binding sites. Both radioligands labeled apparently homogeneous populations of high affinity, stereoselective, saturable sites, determined from analysis of saturation isotherms. [3H]Spiroperidol bound to more than twice as many sites as [3H]dopamine, and antagonist/[3H]spiroperidol competition data were consistent with a single population of receptors. Antipsychotic drugs competed with both high and low affinities for two fractions of [3H]dopamine-binding sites, but for most drugs, their potencies at even the high affinity component were significantly less than their affinities at D2 receptors. The [3H]dopamine-binding sites were altered by kainic acid lesions of the striatum, phenoxybenzamine treatment of tissue homogenates, or reserpine pretreatment of rats. These changes were different from previous reports of alterations in either D2 or D1 dopaminergic receptors. These and other differences in binding properties suggest that [3H]dopamine binds to sites distinct from either D1 or D2 receptors.

Volume 26, Issue 3, pp. 439-451, 11/01/1984
Copyright © 1984 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
ScienceHome page
B. Zeeberg, R. Gibson, and R. Reba
Elevated D2 dopamine receptors in drug-naive schizophrenics
Science, February 12, 1988; 239(4841): 789 - 791.
[PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1984 by the American Society for Pharmacology and Experimental Therapeutics